期刊文献+

多层螺旋CT配合阴道超声评价血清硫酸脱氢表雄酮水平与多囊卵巢综合征排卵障碍的相关性 被引量:2

Multi-layered screw CT coordinated by transvaginal ultrasound for evaluating relationship between polycystic ovarian syndrome induced ovulatory obstacle and level of dehydroepiandrosterone sulfate
下载PDF
导出
摘要 目的应用经多层螺旋CT配合阴道超声评价硫酸脱氢表雄酮(DHE-AS)水平与多囊卵巢综合征(PCOS)排卵障碍的相关性。方法选取2009年3月至2015年5月在该院诊治的198例排卵障碍患者为研究对象,将其中96例PCOS排卵障碍患者设为PCOS组(DHE-AS阳性组58例,DHE-AS阴性组38例),将102例非PCOS排卵障碍患者设为非PCOS组;同时选取因男方因素就诊而排卵正常的100例不孕症患者为对照组。应用多层螺旋CT检测患者卵巢多囊样改变临床表征,阴道彩色多普勒超声诊断仪监测患者排卵情况;采用放射免疫法测定血清DHE-AS水平。结果 PCOS组、非PCOS组和对照组患者血清DHE-AS的检测平均值分别为(1 055.71±169.58)、(795.84±137.72)、(274.15±49.56)ng/m L,PCOS组的测定值显著高于非PCOS组和对照组,差异均有统计学意义(P<0.05);DHE-AS阳性组患者的平均排卵周期、卵泡未破裂黄素化发生率和黄体生成素峰形成率[(108.72±23.56)d、24.14%(14/58)和46.55%(27/58)]均明显高于DHEAS阴性组[(14.58±3.94)d、7.89%(3/38)、26.32%(10/38)],而提前排卵率、排卵率和卵泡未破裂黄素化平均发生周期[3.45%(2/58)、10.34%(6/58)、(3.57±1.38)d]均明显低于DHE-AS阴性组[26.32%(10/38)、92.11%(35/38)、(18.95±4.24)d],差异均有统计学意义(P<0.05);Pearson相关分析结果显示,DHE-AS水平与平均排卵周期、卵泡未破裂黄素化发生率和黄体生成素峰形成率呈正相关(r=0.471、0.684、0.360,P=0.017、0.006、0.034);与提前排卵率、排卵率和卵泡未破裂黄素化平均发生周期呈负相关(r=-0.371、-0.753、-0.556,P=0.032、0.002、0.014)。结论过高水平的DHE-AS是导致PCOS排卵障碍的重要因素。 Objective To evaluate the relationship between polycystic ovarian syndrome (PCOS) induced ovulatory ob-stacle and the level of dehydroepiandrosterone sulfate (DHE-AS) by using multi-layered screw CT coordinated by transvaginal ul-trasound. Methods 198 cases of ovulatory obstacle in our hospital from March 2009 to May 2015 were selected as the research subjects,among them 96 cases of PCOS induced ovulatory obstacle as the PCOS group (DHE-AS positive group,58cases,DHE-AS negative group,38 cases) and 102 cases of non-PCOS-induced ovulatory obstacle as the non-PCOS group,at the same time 100 infertile women with normal ovulation due to male factors were selected as the control group;the clinical manifestations of PCOS were detected by multi-layered screw CT and the ovulation situation was monitored by transvaginal color Doppler ultrasound. The DHE-AS level was detected by radioimmunity method. Results The mean values of DHE-AS in the PCOS group,non-PCOS group and control group were (1 055.71±169.58),(795.84±137.72),(274.15±49.56)ng/mL respectively. The detection value in the PCOS group was significantly higher than that in the non-PCOS group and control group,the differences were statistically sig-nificant (P〈0.05);the average ovulation cycle,follicular unruptured luteinized occurrence rate and luteinizing hormone peak for-mation rate in the DHE-AS positive group were(108.72±23.56)d,24.14%(14/58) and 46.55%(27/58) respectively,which were significantly higher than(14.58±3.94)d,7.89%(3/38) and 26.32%(10/38) in the DHE-AS negative group,while the rate of ahead ovulation,ovulation rate and follicular unruptured luteinized average cycle were 3.45%(2/58),10.34%(6/58) and(3.57±1.38)d, which were obviously lower than 26.32%(10/38),92.11%(35/38) and(18.95±4.24) d in the DHE-AS negative group,the differ-ences were statistically significant(P〈0.05);the Pearson correlation analysis results showed that the DHE-AS level was positively correlated with average ovulation cycle and follicular unruptured luteinized occurrence rate (r=0.471,0.684,0.360,P=0.017,0.006, 0.034),and was negatively correlated with the luteinizing hormone peak formation rate, rate of ahead ovulation ,ovulation rate and follicular non-rupture luteinized average cycle(r=-0.371,-0.753,-0.556,P=0.034,0.032,0.002,0.014). Conclusion The exces-sive high level of DHE-AS is an important factor leading to the PCOS induced ovulation obstacle.
作者 陈刚 周煜
出处 《现代医药卫生》 2015年第18期2739-2741,共3页 Journal of Modern Medicine & Health
关键词 多囊卵巢综合征 无排卵 体层摄影术 X线计算机 阴道/超声检查 去氢表雄酮 Polycystic ovary syndrome Anovulation Tomography,X-ray computed Vagina/ultrasonography Dehydroepiandrosterone
  • 相关文献

参考文献16

  • 1Li RH, Ng EH. Management of anovulatoryinfertility[J]. Best Pract Res Clin Obstet Gynaecol, 2012,26 (6) : 757-768.
  • 2Lauritsen MP ,Pinborg A ,Loft A ,et al. Revised criteria for PCOS in WHO Group Ⅱ anovulatory infertility-a revival of hypothalamic amenorrhoea?[J]. Clin Endocrinol, 2015,82 ( 4 ) : 584-591.
  • 3Siristatidis CS, Vrachnis N, Creatsa M, et al. In vitro maturation in sub- fertile women with polycystic ovarian syndrome undergoing assisted repro- duction[J]. Cochrane Database Syst Rev, 2013,10 :CD006606.
  • 4Urbanski HF, Mattison JA, Roth GS, et al. Dehydroepiandrosterone sul- fate (DHEAS) as an endocrine marker of aging in calorie restriction stu- dies[J]. Exp Gerontol,2013,48(10) :1136-1139.
  • 5周永昌,郭万学.超声医学[M].3版.北京:科学技术文献出版社,2000:381.
  • 6Murri M, Luque-Ramirez M, Insenser M, et al. Circulating markers of oxi- dative stress and polycystic ovary syndrome (PCOS):a systematic review and meta-analysis[J]. Hum Reprod Update, 2013,19 (3) : 268-288.
  • 7Zhu W, Chen M, Fu Z, et al. Repeat transvaginal ultrasound-guided ovarian interstitial laser treatment improved the anovulatory status in women with polycystic ovarian syndrome[J]. Eur J Obstet Gynecol Reprod Biol,2012, 162(1 ) :50-54.
  • 8Guzman L, Ortega-Hrepich C,Polyzos NP, et al. A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count[J]. Hum Reprod, 2013,28 ( 5 ) : 1261 - 1266.
  • 9Peitsidis P, Agrawal R. Role of vascular endothelial growth factor in women with PCO and PCOS:a systematic review[J]. Reprod Biomed Online, 2010, 20 (4) : 444-452.
  • 10Atiomo WU, Khalid S,Ziauddin A, et al. Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome[J]. Exp Rev Proteomics, 2009,6 (5) : 469-499.

二级参考文献15

  • 1Keay SD, conception Liversedge NH, Mathur RS, et al. Assisted following poor ovarian response to gonadotrophin stimulation [ J ]. Br J Obstet Gynaecol, 1997, 104(5) : 521-527.
  • 2Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF[J]. Hum Reprod, 2011, 26 (10): 2742-2749.
  • 3Haning R J, Hackett RJ, Flood CA, et al. Plasma dehydroepiandrosterone sulfate serves as a prehormone for 48% of follicular fluid testosterone during treatment with menotropins [J]. J Clin Endocrinol Metab, 1993, 76(5) : 1301-1307.
  • 4Casson PR, Lindsay MS, Pisarska MD, et al. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders : a case series [ J ]. Hum Reprod, 2000, 15(10): 2129-2132.
  • 5Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? [J]. Hum Reprod, 2011, 26(8): 1941-1944.
  • 6Wiser A, Gonen O, Ghetler Y, et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study [J~. Hum Reprod, 2010, 25(10): 2496-2500.
  • 7Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles [J]. Fertil Steril, 2004, 81 (6) : 1713-1714.
  • 8Frattarelli JL, Gerber MD. Basal and cycle androgen levels correlate with in vitro fertilization stimulation parameters but do not predict pregnancy outcome [J~. Fertil Steril, 2006, 86(1) : 51-57.
  • 9Hossein RB, Hormoz B, Shahrokh TE, et al. Testosterone and dehydroepiandrosterone sulphate levels and IVF/ICSI results [J]. Gynecol Endocrinol, 2009, 25(3) : 194-198.
  • 10Orentreich N, Brind JL, Rizer RL, et al. Age changesand sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood [ J ]. J Clin Endocrinol Metab, 1984, 59(3) : 551-555.

共引文献27

同被引文献21

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部